Improving immunotherapy in solid tumors using FMT.

Cancer treatments have seen massive breakthroughs with immunotherapy, which involves drugs that help the body's immune system find and destroy cancer cells. A common type of these drugs, called first-line immune checkpoint inhibitors, works well for some patients but not all. Recently, doctors have discovered an unusual way to make these drugs more effective: fecal microbiota transplantation, which is the process of transferring healthy gut bacteria from a donor into a patient.

According to recent clinical trials, combining these bacterial transplants with standard immunotherapy is showing promising results with an acceptable safety profile. This combined approach has provided clinical benefits for patients battling several types of solid tumors. Specifically, it has proven helpful in treating certain kidney cancers, severe skin cancers like cutaneous melanoma, and non-small cell lung cancer.

The success of this therapy comes down to how the transplanted bacteria change the patient's internal environment. The procedure remodels the gut microbiome by removing harmful bacteria and altering how the body manages its immune and metabolic responses. This internal makeover essentially primes the body to respond better to cancer drugs. However, it is important to note that current summaries of these trials lack specific details, such as the exact number of patients treated, precise success rates, and how long the patients were tracked after treatment.